Tags

Type your tag names separated by a space and hit enter

Validation of the Chinese version of the NUCOG cognitive screening tool in patients with epilepsy, dementia and other neurological disorders.
J Clin Neurosci. 2014 Jun; 21(6):980-7.JC

Abstract

We aimed to develop and validate a Chinese version of the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) for use in Chinese-speaking subjects internationally. Patients and healthy controls were recruited from two hospitals between July and October 2012. Receiver operating characteristic (ROC) curves were utilized to test criterion validity. Convergent validity was assessed via correlations between NUCOG and the Mini-Mental State Examination (MMSE). Reliability was measured by internal consistency (Cronbach's α). Patients with epilepsy (n=144), neurological diseases (n=81), dementia (n=44), and controls (n=260) completed the NUCOG and the MMSE. Overall, both NUCOG and MMSE scores differed significantly across the four groups with the highest scores in the control group and the lowest in the dementia group (p<0.0001). The NUCOG scores could differentiate between patients with certain seizure types, stroke and transient ischemic attack. Compared to the MMSE, the NUCOG exhibited a higher area under the ROC curve. The convergent validity was substantially correlated, and internal consistency was very high (0.922). The Chinese version of NUCOG was demonstrated to be a sensitive and reliable screening tool for cognitive impairment in a Chinese-speaking population not only in China, but also in countries where there is a sizeable population of ethnic Chinese. Additionally, our study also showed the NUCOG could better differentiate cognitive function in patients with certain seizure types, stroke and transient ischemic attack than the MMSE. This potentially expands the clinical usefulness of NUCOG, enabling clinicians to measure the cognitive profile of patients with epilepsy and ischemic cerebrovascular diseases.

Authors+Show Affiliations

School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia. Electronic address: ShuChuen.Li@newcastle.edu.au.Neurology Department, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.Neurology Department, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia; Melbourne Neuropsychiatry Centre, Melbourne Health and University of Melbourne, VIC, Australia.Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia; Melbourne Neuropsychiatry Centre, Melbourne Health and University of Melbourne, VIC, Australia.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Validation Study

Language

eng

PubMed ID

24507711

Citation

Gao, Lan, et al. "Validation of the Chinese Version of the NUCOG Cognitive Screening Tool in Patients With Epilepsy, Dementia and Other Neurological Disorders." Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, vol. 21, no. 6, 2014, pp. 980-7.
Gao L, Li SC, Xia L, et al. Validation of the Chinese version of the NUCOG cognitive screening tool in patients with epilepsy, dementia and other neurological disorders. J Clin Neurosci. 2014;21(6):980-7.
Gao, L., Li, S. C., Xia, L., Pan, S., Velakoulis, D., & Walterfang, M. (2014). Validation of the Chinese version of the NUCOG cognitive screening tool in patients with epilepsy, dementia and other neurological disorders. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 21(6), 980-7. https://doi.org/10.1016/j.jocn.2013.09.020
Gao L, et al. Validation of the Chinese Version of the NUCOG Cognitive Screening Tool in Patients With Epilepsy, Dementia and Other Neurological Disorders. J Clin Neurosci. 2014;21(6):980-7. PubMed PMID: 24507711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Validation of the Chinese version of the NUCOG cognitive screening tool in patients with epilepsy, dementia and other neurological disorders. AU - Gao,Lan, AU - Li,Shu-Chuen, AU - Xia,Li, AU - Pan,Songqing, AU - Velakoulis,Dennis, AU - Walterfang,Mark, Y1 - 2013/12/01/ PY - 2013/04/15/received PY - 2013/09/12/revised PY - 2013/09/24/accepted PY - 2014/2/11/entrez PY - 2014/2/11/pubmed PY - 2014/12/20/medline KW - Cognition KW - Dementia KW - Epilepsy KW - Mini-Mental State Examination KW - Neuropsychiatry Unit Cognitive Assessment Tool Screening SP - 980 EP - 7 JF - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JO - J Clin Neurosci VL - 21 IS - 6 N2 - We aimed to develop and validate a Chinese version of the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) for use in Chinese-speaking subjects internationally. Patients and healthy controls were recruited from two hospitals between July and October 2012. Receiver operating characteristic (ROC) curves were utilized to test criterion validity. Convergent validity was assessed via correlations between NUCOG and the Mini-Mental State Examination (MMSE). Reliability was measured by internal consistency (Cronbach's α). Patients with epilepsy (n=144), neurological diseases (n=81), dementia (n=44), and controls (n=260) completed the NUCOG and the MMSE. Overall, both NUCOG and MMSE scores differed significantly across the four groups with the highest scores in the control group and the lowest in the dementia group (p<0.0001). The NUCOG scores could differentiate between patients with certain seizure types, stroke and transient ischemic attack. Compared to the MMSE, the NUCOG exhibited a higher area under the ROC curve. The convergent validity was substantially correlated, and internal consistency was very high (0.922). The Chinese version of NUCOG was demonstrated to be a sensitive and reliable screening tool for cognitive impairment in a Chinese-speaking population not only in China, but also in countries where there is a sizeable population of ethnic Chinese. Additionally, our study also showed the NUCOG could better differentiate cognitive function in patients with certain seizure types, stroke and transient ischemic attack than the MMSE. This potentially expands the clinical usefulness of NUCOG, enabling clinicians to measure the cognitive profile of patients with epilepsy and ischemic cerebrovascular diseases. SN - 1532-2653 UR - https://www.unboundmedicine.com/medline/citation/24507711/Validation_of_the_Chinese_version_of_the_NUCOG_cognitive_screening_tool_in_patients_with_epilepsy_dementia_and_other_neurological_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0967-5868(13)00618-8 DB - PRIME DP - Unbound Medicine ER -